Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
- Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells
- Advisory Board unites distinguished experts in corporate strategy, clinical haemato-oncology, protein engineering and early-stage drug discovery and development
- Grant funding secured from innovation-supporting Austrian government bodies FFG and AWS
Graz, Austria, 28 April 2025 – Cycuria Therapeutics (Cycuria), a preclinical stage biotechnology company pioneering breakthrough protein-based targeted therapies for haematological cancers, today announces the formation of a distinguished Advisory Board and successful approval of grant funding from two leading Austrian national funding organisations, the FFG (Forschungs Förderungs Gesellschaft) and the AWS (Austria Wirtschaftsservice Gesellschaft mbH). The grant funding follows an initial Seed investment from Wieland Capital (WPMB GmbH), a Munich-based family office.
